Maria Croyle, R.Ph., Ph.D. and Kristina Jonsson-Schmunk, from the University of Texas at Austin
(Monday, November 3, 2014) – The following are soundbites from Maria Croyle, R.Ph., Ph.D., from the University of Texas at Austin College of Pharmacy, regarding a nasal vaccine in development that has been shown to provide long-term protection for non-human primates against the deadly Ebola virus. Results from a small pre-clinical study represent the only proof to date that a single dose of a non-injectable vaccine platform for Ebola is long-lasting, which could have significant global implications in controlling future outbreaks.
This work is being presented at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world’s largest pharmaceutical sciences meeting, in San Diego, November 2 to 6.
Maria Croyle, R.Ph., Ph.D. and Kristina Jonsson-Schmunk, from the University of Texas at Austin bites:
SOUNDBITE #1 (Croyle)
THE MAIN ADVANTAGE OF OUR VACCINE PLATFORM OVER THE OTHERS IN CLINICAL TESTING IS THE LONG-LASTING PROTECTION AFTER A SINGLE INTRANASAL DOSE. MOREOVER, THE NASAL SPRAY IMMUNIZATION METHOD IS MORE ATTRACTIVE THAN A NEEDLE VACCINE GIVEN THE COSTS ASSOCIATED WITH SYRINGE DISTRIBUTION AND SAFETY (:15)
SOUNDBITE #2 (Jonsson-Schmunk)
ALTHOUGH PROGRESS HAS BEEN MADE IN UNDERSTANDING THE VIRUS’ BIOLOGY, NO LICENSED VACCINES OR TREATMENTS CURRENTLY EXIST. THERE IS A DESPERATE NEED FOR A VACCINE THAT NOT ONLY PREVENTS THE CONTINUED TRANSMISSION FROM PERSON TO PERSON, BUT ALSO AIDS IN CONTROLLING FUTURE INCIDENCES (:15)